Company profile: Aledia
1.1 - Company Overview
Company description
- Provider of 3D LED and microLED display technologies, including silicon nanowire microLEDs for energy-efficient, high-resolution screens; WireLED using gallium nitride nanorods on silicon to cut cost and growth time; Nova Blue microLED for cost-effective mass production in small/mid-size displays; 3D microLEDs for smart devices and large displays; and SmartPixel for flexible, deformable, transparent HDR screens.
Products and services
- MicroLED Technology: Aledia engineers nanowire-architected 3D microLEDs on silicon, producing energy-efficient, high-resolution display screens for various applications via its unique 3D architecture
- 3D microLED Products: Aledia builds industrial-grade screens with high brightness, contrast, color range, and purity for smart devices and large displays, exploiting 3D microLED architecture
- Nova Blue microLED (ALD-LD-000X): Aledia produces a mass-production-ready microLED product engineered for cost-effective fabrication, targeting small and mid-size displays in tablets and laptops.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aledia
Tacere Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for serious infectious diseases, including Hepatitis C (HCV), leveraging RNA interference (RNAi), gene medicine, and novel biologicals, with proprietary expertise in identifying and developing RNAi therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tacere Therapeutics company profile →
Eden Innovations
HQ: Australia
Website
- Description: Provider of clean energy solutions, producing and selling EdenCrete concrete admixture and OptiBlend retrofit dual-fuel technology for diesel generator sets, operating through Eden Innovations LLC and Eden Energy (India) Pvt Ltd.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eden Innovations company profile →
Revalesio
HQ: United States
Website
- Description: Provider of therapeutics targeting inflammatory and neurological diseases, including RNS60, a neuroprotective drug candidate that activates signaling pathways to promote mitochondrial biogenesis and cell survival. Conducts Phase 2 clinical trials in ischemic stroke and ALS, and advances discovery programs in traumatic brain injury, Alzheimer’s disease, and Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revalesio company profile →
Zyvex
HQ: United States
Website
- Description: Provider of molecular nanotechnology innovations focused on developing atomically precise manufacturing. Founded in 1997 as the first molecular nanotechnology company; by 2007 its research had been commercialized into several products and it later restructured into separate companies to focus on product lines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zyvex company profile →
Arcturus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage mRNA medicines and vaccines, including ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved for use in adults; investigational therapies ARCT-032 and LUNAR-CF for cystic fibrosis and LUNAR-OTC for ornithine transcarbamylase deficiency; and platforms STARR™ mRNA Technology and LUNAR® lipid-mediated delivery for nucleic acid drug delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcturus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aledia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aledia
2.2 - Growth funds investing in similar companies to Aledia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aledia
4.2 - Public trading comparable groups for Aledia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →